(Q43762374)

English

Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report (English)

1 reference

Europe PubMed Central

26 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic liver disease

1 reference

based on heuristic

inferred from title

author name string

S Saigal

1

1 reference

Europe PubMed Central

26 November 2017

S R Agarwal

2

1 reference

Europe PubMed Central

26 November 2017

H P Nandeesh

3

1 reference

Europe PubMed Central

26 November 2017

S K Sarin

4

1 reference

Europe PubMed Central

26 November 2017

publication date

1 September 2001

1 reference

Europe PubMed Central

26 November 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

26 November 2017

16

1 reference

Europe PubMed Central

26 November 2017

9

1 reference

Europe PubMed Central

26 November 2017

1028-1032

1 reference

Europe PubMed Central

26 November 2017

Tuberculosis and poverty

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02570.X

21 January 2018

Drug treatment of tuberculosis--1992

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02570.X

21 January 2018

Preventive treatment of tuberculosis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02570.X

21 January 2018

In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02570.X

21 January 2018

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02570.X

21 January 2018

Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02570.X

21 January 2018

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02570.X

21 January 2018

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02570.X

21 January 2018

Identifiers

10.1046/J.1440-1746.2001.02570.X

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43762374&oldid=2103119530"